Bronchogen

Overview

Bronchogen is a short synthetic tetrapeptide belonging to the family of tissue-specific "peptide bioregulators" (sometimes called cytogens) developed by Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. Like other members of that family — for example Epitalon and Thymalin — it is promoted for a specific tissue, in this case bronchial / respiratory tissue.

The honest evidence picture is limited, older, and mostly Russian or preclinical. The only clearly verifiable peer-reviewed primary study located is an in-vitro biophysical study (Monaselidze, Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011) reporting that the peptide slightly raises the melting temperature of isolated DNA. That is a biophysical observation, not a demonstration of therapeutic efficacy. Broader claims about tissue repair, mucin/surfactant genes, or bronchial-epithelium effects appear largely in vendor and secondary material and could not be verified against primary peer-reviewed sources in this search — treat them as hypothesis.

There are no published human clinical trials in respiratory patients that could be located, and Bronchogen is not an approved medicine anywhere confirmed in the sources found. It is sold only as a research reagent.

Chemistry and structure

Bronchogen is described as a linear tetrapeptide built from four amino acids — alanine, glutamic acid, aspartic acid and leucine — but, as noted above, the order of those residues is reported inconsistently across primary sources.

The molecular formula (C18H30N4O9) and molecular weight (~446.45 g/mol) are consistent across the PubChem entries found. No CAS number could be located.

Mechanism of action

The mechanisms attributed to Bronchogen should be read cautiously: only the first is backed by a verifiable primary study, and it is a biophysical result rather than a therapeutic one.

• In vitro, Bronchogen raises the melting (denaturation) temperature of DNA by ~3.1°C. Using DNA from calf thymus and mouse liver, the effect appeared within a narrow peptide/DNA base-pair molar ratio (r ≈ 0.01–0.055) and was consistent with a DNA-stabilizing effect via non-specific binding to nitrogenous bases (no AT/GC preference). This is a biophysical observation, not evidence of clinical benefit. [In vitro] — Monaselidze, Khavinson et al., Bull Exp Biol Med 2011 (PMID 21240358)
• Proposed to act as a Khavinson "peptide bioregulator" that binds DNA/chromatin and modulates tissue-specific gene expression in bronchial/pulmonary tissue (e.g. epithelial differentiation, mucin or surfactant genes). Specific gene targets sometimes cited by vendors were not verified against a primary peer-reviewed source in this search. [Hypothesis] — vendor / secondary literature; specific gene-target claims unverified
• Reportedly synthesized on the basis of polypeptide fractions isolated from bronchial mucosa, and described as intended to stimulate reparative processes in bronchial cell cultures. This origin/repair claim was not confirmed against a primary source in this search. [Hypothesis] — vendor / secondary literature

Research and evidence

Human evidence. There are no well-established human clinical trials of Bronchogen. No published trials in respiratory disease could be located in searched primary databases (PubMed) as of 2026-07-08. Claims of respiratory or tissue benefit are preclinical or vendor-derived and are not supported by human data. Human pharmacokinetics, dosing, and safety data were not found.

Status and regulation

• Not approved by the FDA or EMA for any indication, and no evidence of a marketing authorization in any Western jurisdiction was found.
• Sold only as a research reagent ("for research use"). Any intended human use would make it an unauthorised (unlicensed) medicine.
• Whether Bronchogen holds any regulatory registration in Russia could not be verified in the sources found (no confirmed Russian registration located).
• WADA (anti-doping) status: not established. No authoritative WADA source could be found; vendor claims are contradictory and unsourced. A WADA class is not asserted here. WADA sport-eligibility is a separate axis from legality in any case.

Safety

• The human safety profile is uncharacterized: no human pharmacokinetic, dosing, or safety data were found. Absence of reported harms reflects absence of study, not a demonstration of safety.
• Material sold as "Bronchogen" is a research chemical; its identity, purity, and contaminant profile cannot be assumed to be controlled.
• As an injectable/reconstituted research peptide, the usual risks of non-sterile injectable products would apply in any unregulated use.

Legal status

Bronchogen is handled as a research reagent / research chemical ("for laboratory research use only"). That classification is not permission for human use: "no specific ban" is not affirmative authorisation, and the compound would become an unauthorised medicine the moment it is intended for human use. No jurisdiction is known, from the sources found, to have approved it as a medicine. Anti-doping status could not be authoritatively sourced and is treated as unknown. This is not legal advice — verify the rules in your own jurisdiction (dated 2026-07-08).

How it compares

Bronchogen is best understood alongside the other short Khavinson "peptide bioregulators", which share the same pattern of bold tissue-specific claims resting on a thin, mostly single-group, largely preclinical evidence base:

• Epitalon — a synthetic pineal-associated tetrapeptide (Ala-Glu-Asp-Gly) from the same school, promoted for longevity, with limited independent replication and very sparse human data.
• Thymalin — a thymus-derived peptide preparation from the same school, registered in Russia as an immunomodulator but not FDA/EMA-approved, with most evidence from one research group.

Compared with these, Bronchogen has an even thinner verifiable record: essentially one in-vitro biophysical paper, and no located human data at all.

Common misconceptions

• "Bronchogen is a proven lung/bronchial therapy." It is not. The only clearly verifiable primary finding is an in-vitro DNA-thermostability result; there are no located human trials.
• "The tissue-repair and gene-regulation mechanisms are established." Those claims are largely vendor-derived and were not verifiable against primary peer-reviewed sources; treat them as hypothesis, not fact.
• "The sequence is settled." Even the order of the four amino acids differs across primary sources (Ala-Asp-Glu-Leu vs Ala-Glu-Asp-Leu vs Glu-Asp-Leu-Ala).
• "Because it's unapproved, it must be WADA-banned (S0)." That inference is invalid. No authoritative WADA source was found; no class code is asserted here.
• "Research-use classification means it's legal to take." It does not. A research reagent becomes an unauthorised medicine the moment it is intended for human use.